NEW TOOLS FOR BASIC NEUROBIOLOGICAL RESEARCH

申请人的描述：该项目提出了一种新的工具的发展 用于研究和治疗慢性疼痛。同相 I是P物质和核糖体之间的有效而特异的结合物 产生失活蛋白皂苷。在第二阶段，该试剂 将通过使其均匀，更具体，更活跃， 并且更易于客户使用。新优化的试剂将是 与I期所用试剂相比， 脊髓背角的受体神经元。数据 与新构建体一起收集的信息可能表明P物质毒素 在疼痛控制中是治疗上有用的。SP-SAP在以下领域的成功 vivo已经表明其它肽-毒素可以商业化。在 为了更全面地解决有关疼痛传播的问题， 提出生产一种结合皮吗啡，一种μ阿片类药物 受体特异性激动剂和皂苷，以进一步描绘 传递疼痛的途径。这种共轭也将引起广泛的兴趣。 一组研究人员。 拟定商业应用： 这些产品有一个小而热情的市场， 神经科学界的基础研究人员。申请人提供 成本和市场规模的详细估计。申请组织 目前市售的用于切除乙酰胆碱的皂苷缀合物 包含细胞。目前没有竞争产品。因此 申请人组织似乎准备好开发该产品。那里 有充分的理由相信，第二阶段的实验将提供一个 为更有效地生产其他目标毒素奠定基础 这将增加公司的产品线。

APPLICANT'S DESCRIPTION: This project proposes development of a new tool for the research and potentially the treatment of chronic pain. In Phase I, a potent and specific conjugate between substance P and the ribosome- inactivating protein saponin was produced. In Phase II, this reagent will be optimized by making it homogeneous, more specific, more active and easier for the customer to use. The newly optimized reagent will be compared to the reagent used in Phase I for ability to eliminate NK-1 receptor-bearing neurons, in the dorsal horn of the spinal cord. Data gathered with the new construct may indicate that the substance P toxin is therapeutically useful in pain management. The success of SP-SAP in vivo has indicated that other peptide-toxins can be commercialized. In order to more fully address questions about pain transmission, it is proposed to produce a conjugate between dermorphin, a mu opioid receptor-specific agonist, and saponin in order to further delineate the pathway of pain transmission. This conjugate will also interest a broad group of researchers. PROPOSED COMMERCIAL APPLICATION: A small but enthusiastic market exists for these products as tools for basic researchers in the neuroscience community. The applicant provides a detailed estimate of cost and market size. The applicant organization currently markets a saponin conjugate for ablation of acetylcholine containing cells. There are currently no competing products. Thus, the applicant organization appears well poised to exploit the product. There is good reason to believe that the Phase II experiments will provide a foundation for more efficient production of additional targeted toxins that will add to the company's product line.